Table 3.
Patients suffering from probable invasive fungal disease.
| Center | Frankfurt | Frankfurt | Frankfurt | Münster | Münster | Münster | Münster | Münster | Münster |
|---|---|---|---|---|---|---|---|---|---|
| Sex/age (years) | f/16.9 | m/9.5 | f/16.8 | m/17.4 | f/15.3 | m/3.9 | m/2.3 | m/17.1 | m/13.3 |
| Malignancy (risk group) | AML | ALL | AML | ALL (HR) | ALL | AML | ALL (MR) | ALL (SR) | AA |
| Chemo/HSCT | HSCT | HSCT | Chemo | Chemo | HSCT | Chemo | Chemo | Chemo | HSCT |
| Time point | Post-engraft | Post-engraft | Re-induction | Induction | Pre-engraft | Induction | Induction | Re-induction | Pre-engraft |
| Risk factors | S, CSA | S | N | N, S | N | N | N, S | S | N |
| Pathogen | Aspergillus | Aspergillus | Aspergillus | Aspergillus | Aspergillus | Aspergillus | Aspergillus | Aspergillus | Aspergillus |
| Site | Lung (imaging, serum GM) | Lung (imaging, serum GM) | Lung (imaging, serum GM, and GM in BAL) | Lung/brain (imaging, serum GM, and GM in BAL) | Lung (imaging, BAL culture) | Lung (imaging, serum GM) | Lung (imaging, serum GM) | Lung (imaging, serum GM) | Lung (imaging, serum GM) |
| Prophylaxis | Antimold (LAMB, Vori∗) | Antimold (Vori) | Antimold (Mica, Posa∗) | No | Antimold (Vori) | Antimold (LAMB) | Antimold (LAMB) | No | Antimold (Vori) |
| Outcome IFD | CR | PR | PR | CR | Death | PR | CR | CR | SD |
| Outcome | Alive | Death unrelated to IFD | Alive | Alive | Death due to IFD | Alive | Alive | Alive | Alive |
f, female; m, male; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ALL-SR, ALL-standard-risk group; ALL-MR, ALL-medium-risk group; ALL-HR, ALL-high-risk group; AA, aplastic anemia; chemo chemotherapy; HSCT, hematopoietic stem cell transplantation; engraft engraftment; N, prolonged neutropenia (<500 neutrophils/mm3 >10 days); S use of corticosteroids at a mean minimum dose of 0.3 mg/kg/day prednisone equivalent for more than 3 weeks; GM, galactomannan; BAL, broncho-alveolar lavage; LAMB, liposomal amphotericin B; Vori voriconazole; Posa posaconazole; Mica micafungin; CR, complete remission; PR, partial remission; SD, stable disease; IFD, invasive fungal disease.